WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 06-Sep-2017 (data as of 05-Sep-2017)
Next overall update 2018
EPI mother and child logo         
Select a country

Development status: Economy in transition GNI / capita (US$): 6'5601 Infant (under 12 months) mortality rate: 282
GDP / capita (US$): 17'7401 Child (under 5 years) mortality rate: 322

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 9'725  9'617  9'504  9'385  9'265  8'123  7'243  6'151 
Births 173  176  178  177  175  141  206  164 
Surviving infants 168  171  172  172  169  133  189  149 
Pop. less than 5 years 891  866  847  814  773  713  939  697 
Pop. less than 15 years 2'253  2'203  2'167  2'127  2'091  2'530  2'405  2'146 
Female 15-49 years 2'654  2'668  2'680  2'692  2'701  2'281  1'832  1'571 

Number of reported cases

(Click for retrospective incidence data for Azerbaijan)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  164  210  2'026 
Mumps
ChartChart
  76  126  6'817 
Pertussis
ChartChart
  18  11  63 
Polio*
ChartChart
 
Rubella
ChartChart
  219 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  13 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Azerbaijan)
Vaccine year result method % card seen                                                
BCG 2010  98  DHS   98  98  98  98  98  98  98 
DTP1 2010  94  DHS   98  98  97  96  95  95  99 
DTP3 2010  81  DHS   98  97  96  94  93  93  98 
DTP4          98  97  97 
IPV1          88 
HepB_BD          99  99  99  99  99 
HepB3 2010  80  DHS   98  97  96  94  93  93 
Hib3          97  96  94  93  91 
JapEnc         
MCV1          98  98  98  98  97  98 
MCV2          98  98  98  98  98 
MenA         
PCV1          98  97  91 
PCV2          97  96  80 
PCV3          97  94  64 
Pol3 2010  85  DHS   98  98  98  97  96  96  98 
Rota1         
RotaC         
RCV1          98  98  98  98 
TT2plus         
PAB         
VAD1          95  96  65  86  93 
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Azerbaijan)
BCG
ChartChart
  98  98  98  98  98  81 
DTP1
ChartChart
  98  97  96  95  94  83 
DTP3
ChartChart
  97  96  94  93  89  76 
HepB3
ChartChart
  97  96  94  93  88 
HepB_BD
ChartChart
  99  99  99  99  98 
Hib3
ChartChart
  97  96  94  93  89 
IPV1
  88 
MCV1
ChartChart
  98  98  98  98  94  67 
MCV2
ChartChart
  98  98  98  98  95 
PCV3
ChartChart
  97  94  64 
Pol3
ChartChart
  98  98  97  96  92  75 
RCV1
ChartChart
  98  98  98  98  94 
RotaC
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 64  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 4-7 days; Yes
DT 6 years; Yes
DTwP 18 months; Yes
DTwPHibHepB 2, 3, 4 months; Yes
HepB_Pediatric birth; Yes
IPV 6 months; Yes
MMR 12 months; 6 years; Yes
OPV 4-7 days; 2, 3, 4, 18 months; Yes
Pneumo_conj 2, 4, 6 months; Yes
VitaminA 12, 18 months; Yes

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2016-2020  2011-2015  2011-2015  2011-2015  2011-2015  2011-2015  2011-2015 
Nº of districts with microplans that include activities to raise immunization coverage number 64  64  64  64  64  64  64 

System performance

Total Nº districts in country number 64  64  64  64  64  64  64 
Nº districts with DTP3 coverage >=80% number 64  64  64  63  63  63  64 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  98  98  98  100 
Nº districts with measles (MCV1) coverage >=95% number 59  56  57  56  51  53  49 
% of districts with MCV1 coverage >=95% From 0 to 100% 92  88  89  88  80  83  77 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% 99  71  40  86  90  87  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  No  No  No 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.